BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38648167)

  • 1. Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease.
    Warren HT; Saeger HN; Tombari RJ; Chytil M; Rasmussen K; Olson DE
    J Med Chem; 2024 May; 67(9):6922-6937. PubMed ID: 38648167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
    Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
    Smith B; Medda F; Gokhale V; Dunckley T; Hulme C
    ACS Chem Neurosci; 2012 Nov; 3(11):857-72. PubMed ID: 23173067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
    Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
    Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
    Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
    J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
    Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
    Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
    Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
    Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DYRK1A inhibition as potential treatment for Alzheimer's disease.
    Stotani S; Giordanetto F; Medda F
    Future Med Chem; 2016 Apr; 8(6):681-96. PubMed ID: 27073990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyrk1 inhibition improves Alzheimer's disease-like pathology.
    Branca C; Shaw DM; Belfiore R; Gokhale V; Shaw AY; Foley C; Smith B; Hulme C; Dunckley T; Meechoovet B; Caccamo A; Oddo S
    Aging Cell; 2017 Oct; 16(5):1146-1154. PubMed ID: 28779511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule.
    Wu YW; HuangFu WC; Lin TE; Peng CH; Tu HJ; Sung TY; Sung TY; Yen SC; Pan SL; Hsu KC
    Int J Biol Macromol; 2024 Feb; 259(Pt 1):129074. PubMed ID: 38163507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
    Pathak A; Rohilla A; Gupta T; Akhtar MJ; Haider MR; Sharma K; Haider K; Yar MS
    Eur J Med Chem; 2018 Oct; 158():559-592. PubMed ID: 30243157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.
    Loaëc N; Attanasio E; Villiers B; Durieu E; Tahtouh T; Cam M; Davis RA; Alencar A; Roué M; Bourguet-Kondracki ML; Proksch P; Limanton E; Guiheneuf S; Carreaux F; Bazureau JP; Klautau M; Meijer L
    Mar Drugs; 2017 Oct; 15(10):. PubMed ID: 29039762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
    Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
    Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M
    Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.
    Demuro S; Sauvey C; Tripathi SK; Di Martino RMC; Shi D; Ortega JA; Russo D; Balboni B; Giabbai B; Storici P; Girotto S; Abagyan R; Cavalli A
    Eur J Med Chem; 2022 Feb; 229():114054. PubMed ID: 34959172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Tau Hyperphosphorylation
    Turab Naqvi AA; Hasan GM; Hassan MI
    Curr Top Med Chem; 2020; 20(12):1059-1073. PubMed ID: 31903881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
    Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
    J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
    Kim H; Lee KS; Kim AK; Choi M; Choi K; Kang M; Chi SW; Lee MS; Lee JS; Lee SY; Song WJ; Yu K; Cho S
    Dis Model Mech; 2016 Aug; 9(8):839-48. PubMed ID: 27483355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.